Purpose : To evaluate the safety and efficacy of balloon-expandable covered stent (CS) for treatment of symptomatic iliac artery in-stent restenosis (ISR). Material and methods: This was a retrospective, single-arm, single-centre study, which included 25 consecutive patients referred for percutaneous endovascular treatment of angiographically proven symptomatic iliac artery ISR using balloon expandable CS. All patients presented with recurrent Rutherford 1 to 3 chronic limb ischaemia that deteriorated over an average period of 45 months after bare stenting. Study’s primary safety outcome measures were peri-procedural (30-days) device-related major complications rate and 12 months patient survival rate, while primary efficacy outcome measure was 12-months clinically-driven target lesion reintervention rate. Secondary endpoints included 12-months binary restenosis rates and 30-day procedure related complication rates. Results: Initial technical success was 100%. No device-related major complications occurred. No patient was lost to follow up. According to Kaplan-Meier analysis target lesion revascularisation-free survival rates were 92% at 6- and 12-months follow up, respectively. Restenosis rates were 8% and 12% at 6- and 12-months follow up, respectively. Survival was 100% (25/25 patients). No major complications were noted (0%). Minor complication rate was 4% (1/25 case of medium size haematoma). Conclusions: The use of a balloon-expandable covered stent seems to achieve promising results in the management of symptomatic iliac artery in-stent restenosis.

Background: Increased left ventricular afterload during peripheral venoarterial-extracorporeal membrane oxygenation (VA-ECMO) support frequently causes hydrostatic pulmonary oedema. Because physiological studies demonstrated left ventricular afterload decrease during VA-ECMO assistance combined with the intra-aortic balloon pump (IABP), we progressively changed our standard practice systematically to associate an IABP with VA-ECMO. This study aimed to evaluate IABP efficacy in preventing pulmonary oedema in VA-ECMO-assisted patients. Methods: A retrospective single-centre study. Results: Among 259 VA-ECMO patients included, 104 received IABP. Weinberg radiological score-assessed pulmonary oedema was significantly lower in IABP+ than IABP– patients at all times after ECMO implantation. This protection against pulmonary oedema persisted when death and switching to central ECMO were used as competing risks (subhazard ratio 0.49, 95% confidence interval (CI) 0.33–0.75; P<0.001). Multivariable analysis retained IABP as being independently associated with a lower risk of radiological pulmonary oedema (odds ratio (OR) 0.4, 95% CI 0.2–0.7; P=0.001) and a trend towards lower mortality (OR 0.54, 95% CI 0.29–1.01; P=0.06). Finally, the time on ECMO free from mechanical ventilation increased in IABP+ patients (2.2±4.3 vs. 0.7±2.0 days; P=0.0003). Less frequent pulmonary oedema and more days off mechanical ventilation were also confirmed in 126 highly comparable IABP+ and IABP– patients, propensity score matched for receiving an IABP. Conclusions: Associating an IABP with peripheral VA-ECMO was independently associated with a lower frequency of hydrostatic pulmonary oedema and more days off mechanical ventilation under ECMO.

Poster: ECR 2013 / C-1319 / Initial experience of breast tumour enhancement in ultrasound after injection of contrast media by: I. Vraka 1, A. Koureas1, E. Panourgias2, D. Dellaportas 1, I. Psychogios 1, A. Dalakidis1, P. Galanis 1, A. Gouliamos1, A. Antoniou 1; 1Athens/GR, 2Athens /GR

Case Reports| March 26 2011 Congenital Bronchial Atresia with a Calcified Mucocele Subject Area: Pharmacology , Pneumology Elias Primetis; Elias Primetis Radiology Department, Aretaieio Hospital, University of Athens, Athens, Greece Search for other works by this author on: This Site PubMed Google Scholar Andreas Koureas; Andreas Koureas Radiology Department, Aretaieio Hospital, University of Athens, Athens, Greece Search for other works by this author on: This Site PubMed Google Scholar Apostolos Dalakidis; Apostolos Dalakidis Radiology Department, Aretaieio Hospital, University of Athens, Athens, Greece Search for other works by this author on: This Site PubMed Google Scholar Thomas Prantzos; Thomas Prantzos Radiology Department, Aretaieio Hospital, University of Athens, Athens, Greece Search for other works by this author on: This Site PubMed Google Scholar Konstantinos Palialexis; Konstantinos Palialexis Radiology Department, Aretaieio Hospital, University of Athens, Athens, Greece Search for other works by this author on: This Site PubMed Google Scholar Gouliamos Athanasios Gouliamos Athanasios Radiology Department, Aretaieio Hospital, University of Athens, Athens, Greece Search for other works by this author on: This Site PubMed Google Scholar Respiration (2011) 81 (6): 511–512. https://doi.org/10.1159/000324270 Article history Published Online: March 26 2011 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Elias Primetis, Andreas Koureas, Apostolos Dalakidis, Thomas Prantzos, Konstantinos Palialexis, Gouliamos Athanasios; Congenital Bronchial Atresia with a Calcified Mucocele. Respiration 1 May 2011; 81 (6): 511–512. https://doi.org/10.1159/000324270 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsRespiration Search Advanced Search Article PDF first page preview Close Modal © 2010 S. Karger AG, Basel2011Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.

Tumoral calcinosis, a rare disease manifesting with periarticular, calcified masses in soft tissues, can be either primary or secondary to a disease, such as systemic sclerosis. In the case reported here, a patient diagnosed with systemic sclerosis presented with hard calcified masses that involved the shoulders and hips.